Page 50 - Read Online
P. 50

Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37                               Page 335

             Ref.   [30]  [64]      [27]       [22]     [24]    [49]   [38]      [37]   [30]    [27]



             Clinical outcomes  No association of ABCC2  c.-24C>T and c.3972C>T   variants with AR, DGF,  graft function or adverse   events  -  No association of   ABCC2 c.-24C>T and  rs12762549 variants with   leukopenia  No association of ABCC2  c.-24C>T and c.1249G>A   variants with AR  No association of  ABCC2 c.1249G>A and  c.3972C>T variants with   DGF or AR No association of ABCC2 No association of ABCC2  c.-24C>T and c.1249G>A c.-24C>T and c.1249G>A  variants wit








             Pharmacokinetics  Donors’ ABCC2 c.1249A   allele was associated   with a reduced peak and   early (AUC 0-2 ) exposure   No association of  ABCC2 c.1249G>A and  c.3972C>T variants with   variants with MPA   exposure (AUC)  ABCC2 c.-24TT   genotype was possibly   associated with higher   MPA C/D (days 3-8)   No association of ABCG2   c.421C>A variant with   MPA or MPAG exposure   (AUC 4-12  or AUC 0-12 )







                 -               to MPA  -     -             MPA C/D                    -       -
            Immunosuppressive   regimen  EC-MPS  Tacrolimus  Corticosteroids  Three-month follow-up  MMF  EC-MPS  Cyclosporine  Tacrolimus  Corticosteroids  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids  One-year follow-up  MMF  Cyclosporine  Tacrolimus  Sirolimus  Corticosteroids  EC-MPS  Tacrolimus  Corticosteroids   One-year follow-up  MMF  Tacrolimus  Corticosteroid-free  One-year follow-up  MMF  Cyclosporine  Tacrolimus  Corticosteroids   40-day follow-up












             Population  148 adult patients   (Brazil)  68 adult patients  (Croatia)  284 pediatric and young   adult patients (USA)  145 adult patients   (Brazil)  97 adult patients (Brazil)  21 adult patients   (Canada)  408 adult patients   (China)  37 adult patients  (China)  148 adult patients   (Brazil)  284 pediatric and young   adult patients (USA)








             Study design  Prospective, multicenter   Prospective   Retrospective (Case-  Control), multicenter   Retrospective (Case-  control)  Prospective  Prospective  Retrospective  Prospective,  Multicenter  (Case-control)  Prospective, multicenter  Retrospective (Case-  Control), multicenter








             Allele frequency  c.-24T: 14%  c.3972T: 32%  c.-24T: 17%  c.1249A: 24%   -  c.-24T: 20%  c.1249A: 22%  c.1249A: 19%   c.3972T: 30%   c.-24T: 19%  c.1249A: 0%   c.-24T: 21% c.1249A: 8%  c.421A: 26%  c.421A: 8%  -











             Variant
                                                                                 rs2231142   (c.421C>A)  rs4491984G>A




             Gene                                                                ABCG2
   45   46   47   48   49   50   51   52   53   54   55